(Q38286246)

English

Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

scientific article published on 15 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 September 2017

1 reference

Europe PubMed Central

Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication (English)

1 reference

Europe PubMed Central

1 September 2017

Alzheimer's disease

0 references

author name string

William James Deardorff

1

1 reference

Europe PubMed Central

1 September 2017

Ahmad Shobassy

2

1 reference

Europe PubMed Central

1 September 2017

George T Grossberg

3

1 reference

Europe PubMed Central

1 September 2017

publication date

15 December 2014

1 reference

Europe PubMed Central

1 September 2017

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 reference

Europe PubMed Central

1 September 2017

15

1 reference

Europe PubMed Central

1 September 2017

1

1 reference

Europe PubMed Central

1 September 2017

7-17

1 reference

Europe PubMed Central

1 September 2017

2014 Alzheimer's disease facts and figures

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Alzheimer disease in the United States (2010-2050) estimated using the 2010 census

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Monetary costs of dementia in the United States.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Therapy for Alzheimer's Disease: How Effective are Current Treatments?

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Alzheimer's disease: clinical trials and drug development

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Cognitive effects of nicotine

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Structural and functional diversity of native brain neuronal nicotinic receptors

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

The use of PET in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Neuronal nicotinic receptors in the human brain

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Nicotine prevents synaptic impairment induced by amyloid-β oligomers through α7-nicotinic acetylcholine receptor activation.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity rela

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Intraindividual cognitive decline using a brief computerized cognitive screening test.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

A neuropsychological test battery for use in Alzheimer disease clinical trials.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.995639

21 January 2018

Identifiers

10.1586/14737175.2015.995639

1 reference

Europe PubMed Central

1 September 2017

1 reference

Europe PubMed Central

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38286246&oldid=1751949655"